Anzeige
Mehr »
Mittwoch, 13.05.2026 - Börsentäglich über 12.000 News
Bahnbrechende KI-Lösung "Ohne Nadelstiche" als Ersatz für herkömmliche Bluttests "unlocked"?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ERZ4 | ISIN: US2528281080 | Ticker-Symbol: 87E
Tradegate
08.05.26 | 15:33
75,50 Euro
+2,72 % +2,00
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
DIANTHUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
DIANTHUS THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
73,0073,5021:48
73,0073,5021:39

Aktuelle News zur DIANTHUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.05.LEADS BIOLABS-B Partner Dianthus Selects Three Priority Indications for LBL-047, Including Sjogren's Syndrome and Lupus3
05.05.Dianthus Therapeutics GAAP EPS of -$0.85 beats by $0.23, revenue of $0.46M beats by $0.1M1
05.05.Dianthus Therapeutics, Inc.: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results337Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Claseprubart granted...
► Artikel lesen
05.05.Dianthus Therapeutics, Inc. /DE/ - 10-Q, Quarterly Report-
DIANTHUS THERAPEUTICS Aktie jetzt für 0€ handeln
01.05.Dianthus Therapeutics, Inc.: Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)1
06.04.Dianthus Therapeutics, Inc.: Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)7
26.03.Dianthus rises as FDA agrees with proposed changes to lead program1
26.03.Dianthus-Aktie: FDA-Update zu Sicherheitsanforderungen stützt Outperform-Rating4
26.03.Dianthus stock gets Outperform rating on FDA safety update1
26.03.Dianthus Therapeutics, Inc. /DE/ - 8-K, Current Report1
16.03.William Blair reiterates Dianthus stock rating on CIDP trial data2
16.03.William Blair bestätigt Dianthus-Rating nach Studiendaten zu CIDP-Medikament3
12.03.Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares194NEW YORK and WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) ("Dianthus" or the "Company"), a clinical-stage biotechnology company dedicated to developing...
► Artikel lesen
11.03.Dianthus Therapeutics prices upsized $625M public offering at $81/share2
11.03.Dianthus prices $625M stock offering at $81 per share3
11.03.Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering170NEW YORK and WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) ("Dianthus" or the "Company"), a clinical-stage biotechnology company dedicated to developing...
► Artikel lesen
10.03.Raymond James upgrades Dianthus stock on CIDP trial results2
09.03.Clear Street raises Dianthus Therapeutics price target on CIDP trial data2
09.03.Clear Street hebt Kursziel für Dianthus Therapeutics nach Studiendaten an6
09.03.Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering1
Weiter >>
55 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1